Ginkgo Bioworks Inks Collaboration With Pfizer Focused On The Discovery Of RNA-Based Drug Candidates
Portfolio Pulse from Benzinga Newsdesk
Ginkgo Bioworks has entered into a collaboration with Pfizer for the discovery of RNA-based drug candidates. Ginkgo will receive an upfront payment and could potentially receive up to $331 million in research fees and development and commercial milestone payments across three programs.
September 27, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ginkgo Bioworks, listed as DNA, has entered into a potentially lucrative partnership with Pfizer. This could lead to increased revenues for the company.
The partnership with Pfizer could potentially bring in significant revenues for Ginkgo Bioworks, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer has entered into a collaboration with Ginkgo Bioworks for the discovery of RNA-based drug candidates. This could potentially lead to the development of new drugs for Pfizer.
The collaboration with Ginkgo Bioworks could potentially lead to the discovery of new RNA-based drugs for Pfizer, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100